• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Combined immunotherapy may improve survival in metastatic pancreatic cancer

byMonica ParksandDavid Wang
January 18, 2015
in Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a phase II trial of 90 patients with metastatic pancreatic adenocarcinoma, the combination of two cancer vaccines, Cy/GVAX and CRS-207, was associated with increased overall survival compared to Cy/GVAX alone.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Previous studies have demonstrated the use of cancer vaccines in the treatment of metastatic pancreatic ductal adenocarcinoma (PDA). GVAX pancreas is a granulocyte-stimulating factor stimulating vaccine given with cyclophosphamide (Cy/GVAX) to induce T-cell activity against mesothelin, a PDA-associated tumor antigen. CRS-207 is a recombinant live-attenuated vaccine designed to increase mesothelin secretion in antigen-presenting cells, and may increase the effectiveness of Cy/GVAX via a heterologous prime/boost mechanism. A previous phase I trial demonstrated increased survival in patients treated with both Cy/GVAX and CRS-207 versus Cy/GVAX alone. The purpose of this study was to present the results of the phase II trial analyzing this synergistic effect. Ninety patients with metastatic PCA were assigned to either Cy/GVAX with CRS-207 or Cy/GVAX alone. The primary outcome was overall survival and safety of the combined immunotherapy. At the conclusion of the trial, patients treated with the combination immunotherapy was associated with a 56% (2.2 months) improvement in overall survival compared to Cy/GVAX alone. The majority of the adverse events associated with the combination immunotherapy were injection site reactions. The results of this trial support the use of combined Cy/GVAX and CRS-207 as a treatment modality of metastatic pancreatic cancer; however, given the small sample size, further randomized control trials are needed to confirm the safety and efficacies of these immunotherapies.

Click to read the study in JCO

Relevant Reading: A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation

In-Depth [randomized controlled trial]: This multicenter, randomized phase II trial included a total of 90 patients with metastatic pancreatic ductal adenocarcinoma (PDA). The patients must have had at least one prior therapy regimen and have a life expectancy of greater than 12 weeks. Patients were randomized at a ratio of 2:1 to the treatment arms, either 2 doses of Cy/GVAX followed by 4 doses of CRS-207, or 6 doses of Cy/GVAX alone. The primary endpoint was overall survival, and secondary endpoints were safety and clinical response to treatment. Mean follow-up was 3.4 months. The authors also assessed mesothelin-specific CD8+ T cells. Mean number of doses given in in the combination arm and Cy/GVAX alone was 5.5(±4.5) and 3.7(±2.2), respectively. At the conclusion of the trial, the overall survival was 6.1 months in the combined arm and 3.9 months with Cy/GVAX alone (HR=0.59; 95%CI: 0.36-0.97; p = 0.02). The most frequent adverse events with the combination arm were injection site reactions (erythema: 77%, induration: 71%, pain: 62%), nausea (53%), vomiting (43%), chills (67%), fever (62%) and fatigue (53%). There was no significant difference in mesothelin-specific CD8+ T cell levels between treatment arms.

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

RELATED REPORTS

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

The Moderna mRNA vaccine prevents COVID-19 infection in adolescents

Image: PD/CDC

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc.No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: pancreatic adenocarcinomavaccine
Previous Post

Abnormal lamellar body exocytosis accounted for abnormalities in inherited ichthyoses

Next Post

Long work hours linked to greater “risky” alcohol use

RelatedReports

RSV positivity associated with reduced serious bacterial infection risk [Classics Series]
Infectious Disease

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

June 24, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
Waning Tdap vaccine effectiveness among adolescents
Infectious Disease

The Moderna mRNA vaccine prevents COVID-19 infection in adolescents

June 20, 2022
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Plant-based CoVLP+AS03 vaccine protects against COVID-19 infection

June 18, 2022
Next Post
Exposure to maternal depression linked to adolescent risk behaviors

Long work hours linked to greater “risky” alcohol use

Study explores energy and nutrient intake from pizza

Study explores energy and nutrient intake from pizza

Socioeconomic gradient in childhood cognitive ability likely multifactorial

Socioeconomic gradient in childhood cognitive ability likely multifactorial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.